Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

18,892 total articles

Recursion Announces Board Transition

Recursion Announces Board Transition

Recursion, a clinical-stage TechBio company focused on AI-driven drug discovery, announced that its founder Chris Gibson, Ph.D., will not seek re-election to the Board of Directors after June 2026 but will continue as a strategic advisor. The company emphasizes continuity and long-term value creation under CEO Najat Khan's leadership, advancing its…

Emergent BioSolutions Reports First Quarter 2026 Financial Results

Emergent BioSolutions Reports First Quarter 2026 Financial Results

Emergent BioSolutions Inc. announced its Q1 2026 financial results, reporting total revenues of $156.1 million, net income of $6.8 million, and adjusted EBITDA of $35.6 million. While revenues exceeded guidance, they declined 30% year-over-year, driven by lower sales in key biodefense medical countermeasure segments. The company secured new partner…

HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2026

HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2026

Home Federal Bancorp, Inc. of Louisiana reported significant increases in net income and earnings per share for the three and nine months ended March 31, 2026, driven by improved net interest margins, increased net interest income, and decreased non-interest expenses. The company also expanded its assets and deposits, while continuing its stock rep…

Cue Biopharma Announces $30 Million Private Placement

Cue Biopharma Announces $30 Million Private Placement

Cue Biopharma announced a $30 million private placement (PIPE financing) through the sale of pre-funded warrants and common stock warrants, aimed at advancing its clinical pipeline, including the development of Ascendant-221, as well as supporting working capital and general corporate purposes. The financing is expected to close in early May 2026, …

CN Statement on UP-NS Amended Merger Re-Application

CN Statement on UP-NS Amended Merger Re-Application

Canadian National Railway Company (CN) issued a statement opposing the amended merger application of Union Pacific and Norfolk Southern, arguing that it fails to adequately address the competitive harms posed by the merger and lacks meaningful remedies as required by the Surface Transportation Board. CN emphasizes the need for strict regulatory con…

Boston Beer Reports First Quarter Financial Results

Boston Beer Reports First Quarter Financial Results

The Boston Beer Company reported first quarter 2026 results showing a 4% decline in depletions and 6.9% decrease in shipments, with net revenue down 4.4%. Despite gross margin improving 100 basis points to 49.3%, the company incurred a substantial non-recurring pre-tax litigation expense of $216 million, resulting in a GAAP diluted loss per share o…

Ryman Hospitality Properties, Inc. Reports First Quarter 2026 Results

Ryman Hospitality Properties, Inc. Reports First Quarter 2026 Results

Ryman Hospitality Properties, Inc. (NYSE: RHP) announced record first quarter 2026 financial results driven by strong performance in its same-store Hospitality segment. The company reported record consolidated revenue of $664.6 million, net income of $69.4 million, and Adjusted EBITDAre of $219.3 million. The hospitality portfolio saw increased boo…

Finwise Bancorp Reports First Quarter 2026 Results

Finwise Bancorp Reports First Quarter 2026 Results

FinWise Bancorp reported Q1 2026 financial results, highlighting $1.7 billion in loan originations, up 38% year-over-year. Net income declined to $2.7 million with diluted EPS of $0.20, compared to previous periods. The quarter saw higher net interest income and margin, driven by growth in credit enhanced loans and strategic programs. However, elev…

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Cue Biopharma has entered an exclusive license agreement to develop and commercialize Ascendant-221, a Phase 2 clinical-stage dual-mechanism anti-IgE monoclonal antibody designed to treat allergic diseases. The company plans a global Phase 2b trial in food allergy after data expected in late 2026 from an ongoing study in chronic spontaneous urticar…

Comstock Inc. to Host Q1 2026 Earnings Call and Business Update

Comstock Inc. to Host Q1 2026 Earnings Call and Business Update

Comstock Inc., a clean energy technology company listed on NYSE American under ticker LODE, will hold its Q1 2026 earnings call and business update webinar on May 7, 2026. The company's CEO and CFO will present financial results and operational updates, followed by a Q&A session. The company focuses on extracting and recycling metals from under-uti…

Alta Equipment Group Announces Date of First Quarter 2026 Financial Results Release, Conference Call and Webcast

Alta Equipment Group Announces Date of First Quarter 2026 Financial Results Release, Conference Call and Webcast

Alta Equipment Group Inc., a leading North American equipment dealership, announced it will release its first quarter 2026 financial results on May 7 after market close, followed by a management conference call and webcast. The company provides material handling, construction, and environmental processing equipment through over 80 locations across …

CubeSmart Reports First Quarter 2026 Results

CubeSmart Reports First Quarter 2026 Results

CubeSmart reported its Q1 2026 operating results showing largely stable performance with same-store revenue growth turning positive. The company posted diluted EPS of $0.36 and adjusted funds from operations (FFO) per share of $0.63, both slightly down year-over-year. CubeSmart expanded its portfolio by opening a new development property in New Yor…

Mohawk Industries Reports Q1 2026 Results

Mohawk Industries Reports Q1 2026 Results

Mohawk Industries reported Q1 2026 net earnings of $117 million, with adjusted EPS of $1.90 on $2.7 billion in net sales, an 8% increase reported but a 2.6% decline on constant currency and days. The company benefited from productivity improvements and restructuring efforts, offsetting inflationary cost pressures and volume decreases, while the com…

The Ensign Group Reports First Quarter 2026 Results; Raises 2026 Annual Earnings and Revenue Guidance

The Ensign Group Reports First Quarter 2026 Results; Raises 2026 Annual Earnings and Revenue Guidance

The Ensign Group, Inc. announced its first quarter 2026 results showing significant growth in earnings and revenue, with GAAP diluted EPS up 21.9% to $1.67 and adjusted EPS rising 21.7% to $1.85. The firm reported increased occupancy and skilled nursing revenue rates, expanded its healthcare operations portfolio with key acquisitions, and raised it…

Westwood Holdings Group, Inc. Reports First Quarter 2026 Results

Westwood Holdings Group, Inc. Reports First Quarter 2026 Results

Westwood Holdings Group, Inc. reported its Q1 2026 results showing growth in assets under management to $18.3 billion, driven by strong performance in Energy and Real Assets strategies and growth in ETFs and private energy secondaries funds. Quarterly revenues totaled $25.0 million, slightly down from the previous quarter but above last year's firs…

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

Cue Biopharma announces the appointment of Shao-Lee Lin, M.D., Ph.D., as CEO, President, and Board Director to steer the company’s transition into a clinical-stage biopharmaceutical company. Dr. Lin brings over 25 years of experience leading biotech firms and advancing drug candidates. The company is progressing its lead autoimmune candidate, CUE-4…